AI in Drug Discovery and IP Ownership: Legal Challenges in Pharmaceutical Innovation

 

AI, Drug Discovery & IP Ownership: Who Owns AI-Created Medicines?

Explore how artificial intelligence is transforming drug discovery and the complex
Intellectual property ownership issues surrounding AI-generated pharmaceuticals.

AUTHOR- NARGIS  

Keywords

AI drug discovery IP ownership, artificial intelligence pharmaceutical patents, AI generated drugs patent law, intellectual property AI medicine 

Introduction

Artificial Intelligence is revolutionising the way new medicines are developed.

Earlier, developing a new medicine would take:

•        10 to 15 years
•        Billions of dollars
•        Thousands of experiments

Today, AI computers can process massive amounts of information in a matter of minutes. They can identify new molecules, predict side effects, and even assist in developing medicines. However, this raises a very significant legal issue:

Who owns a new medicine if AI assists in its development?
 Is it:

•      The scientist?
•       The company?
•        The AI developer?
•           Or the AI itself?

This is where intellectual property law gets tricky.

How AI Is Used in Developing Medicines

 AI works by processing massive amounts of information such as:

•  Patient medical records
• Chemical compound libraries
• Genetic information
• Clinical trial data

Instead of conducting thousands of experiments manually, AI can predict which molecule will work best.

For example, companies such as DeepMind have created computers that can predict protein structures. This is a critical step because knowing protein structures helps scientists develop better medicines.

Large pharmaceutical companies such as Pfizer and Novartis are also using AI computers to accelerate the development of new medicines.

AI computers do not get tired. They can process millions of combinations in a matter of hours. This is why AI is becoming so powerful in the field of medicine.

The Big Legal Question: Can AI Be an Inventor?

Under current patent laws in most countries:

Inventors must be human beings according to current patent laws, which apply throughout most countries.

Patent law originates from the concept that human intellect produces unique inventions.

But what happens if:

•        AI creates an entirely new molecular structure?
•        The molecule was not conceived by any human being?
•        The AI system produced the results without any human assistance?

This situation marks the beginning of the problem. Currently, AI systems lack legal recognition as inventors.

 A Famous Legal Example

The case established an important legal precedent through its examination of DABUS which Stephen Thaler developed as an artificial intelligence system. The patent applications identified AI as the inventor according to this case.

Patent offices in:

• United States
• United Kingdom
• Europe
• Australia

The application received rejection from patent offices. The reason was simple: The law requires that an inventor must be a human being. The ruling establishes direct implications for AI-based drug discovery research. 

So Who Owns an AI-Discovered Drug?

 At present, ownership usually goes to:

1. The Human Researcher

A scientist becomes an inventor when they lead the research process while using AI as a research instrument.

2. The Company

The company that employs researchers usually secures patent rights for work performed during their employment.

3. The Organisation Funding the Research

Ownership rights are determined through contract agreements.

The process of establishing human involvement becomes problematic when AI operates with substantial autonomy. Future legal conflicts will emerge because of this issue.

Why IP Ownership Is So Important in Pharma

Drug development costs require high financial investments. Companies invest billions of dollars in:

•        Research
•        Testing
•        Clinical trials
•        Regulatory approvals

Without patents, competitors could copy the drug immediately. Patents provide companies with exclusive rights to their products, which last for 20 years, allowing them to recover their research expenditures. Companies willBGTEto conductAI research when AI-generated drugs face patenting issues.

Another Problem: Who Owns the Output of AI?

Imagine this situation:

• A tech company develops an AI tool.
• A pharma company uses that AI tool.
• The AI system develops a new drug formula.

Now the question is: Does the patent belong to:

• The AI software company?
• The pharma company?
• Both?

The answer depends on the contracts between them. In modern research collaborations, contracts must clearly mention:

• Who owns the data?
• Who owns the results?
• Who can file patents?
• How will profits be shared?

 Lawsuits will emerge when the contracts become difficult to understand.

AI Tool vs AI Creator

People can analyses AI applications in law through two main perspectives:

View 1: AI Is Just a Tool

A microscope exists as a scientific instrument used to examine small objects but The human using it is still the inventor.Presently most countries consider AI systems to function as tools.

View 2: AI Is an Independent Creator

The law needs to change if AI can create works without any human help. Most legal systems now accept the first perspective.

 Ethical Questions

This issue has both legal and ethical dimensions. Some important questions are:

•           If AI discovers a life-saving drug, should it be very expensive?
• ·       Should technology that uses public data be privately owned?
• ·       Should AI innovation benefit everyone equally?

The upcoming years will see a major argument about how to balance public health needs with profit requirements.

What Might Happen in the Future?

 Laws may undergo changes during the upcoming years. The possible changes will include:

•        The legal recognition of AI-assisted inventorship
•        The establishment of new patent standards
•        The creation of distinct regulations for AI advancements
•        The establishment of regulations requiring human oversight

The government establishes a progressive approach to fundamental transformations. Human participation remains essential for legal purposes at this moment.

Final Thoughts

Artificial intelligence (AI) has significantly influenced the drug discovery process in various positive ways. AI allows for:

• More rapid drug development;
• Less expensive drug development;
• More precise drug development.

However, the current state of intellectual property (IP) is based on "human" creation. Currently:

• AI is not able to be listed as the inventor of a patent.
• A person needs to be named in a patent in order for the patent to be valid.
• Ownership will continue to be governed primarily by a contract or employment agreement

As AI evolves and becomes increasingly autonomous, the laws regarding intellectual property will also need to change. In the interim, companies who are using AI will need to be diligent in developing an intellectual property strategy to limit the potential of future legal issues.